Clinical Research
Filter News
Found 128,771 articles
-
"For the first time in history, medicine has become information." That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.
-
The T cell response was measured with immunoSEQ® T-MAP™ COVID, a clinical test developed by Adaptive Biotechnologies.
-
A breakthrough study has found that altering the genetic makeup of malaria-carrying mosquito species could be the key to stopping the spread of the malaria virus and finally eradicating the disease.
-
Blueprint, MD Anderson Cancer Center Accelerate Research Partnership To Develop Cancer Therapies
7/28/2021
The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2). -
Biogen reportedly withdrew a paper it had submitted to the medical journal JAMA after the publication requested edits before publication. It’s standard for a technical journal to request edits, but it is the nature of the edits—and in this case, the nature of the study— that raises questions.
-
Ring Therapeutics hopes to bring in a “new era of gene therapies” to rise above the challenges of current options. A cohort of investors bought into the hope with a $117 million Series B funding round.
-
Tempus Unveils Its Scalable Tumor Organoid Screening Platform In Cell Reports Study
7/28/2021
Tempus, a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform.
-
New consensus disease definitions to aid care, accelerate research for cancer patients with side effects from immunotherapies
7/28/2021
A paper outlining consensus disease definitions for neurological toxicities in cancer patients undergoing immune checkpoint inhibitor treatment was published this week in the Journal for ImmunoTherapy of Cancer (JITC) by a team of physicians at 16 institutions (https://pubmed.ncbi.nlm.nih.gov/34281989/).
-
New research reveals most Americans can’t identify the symptoms of depression
7/28/2021
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor.
-
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
7/28/2021
ALX Oncology Holdings Inc. in partnership with Merck, known as MSD outside the United States and Canada, announced the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA®, Merck’s anti-PD-1 therapy, and standard chemotherapy for the treatment of patients with advanced head and neck squamous cell carcinoma.
-
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
7/28/2021
MediWound Ltd. announced a positive outcome from a planned interim sample size re-estimation of its ongoing EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers, designed to assess the safety and efficacy of EscharEx compared to gel vehicle and non-surgical standard-of-care.
-
Tarsier Pharma, in Collaboration with Uveitis Experts, Published a Research Article about a New Grading Image Scale for Assessing Uveitis
7/28/2021
Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced the publication of a research article that was produced in collaboration with uveitis Key Opinion Leaders, including Prof. de Smet, Prof. Cunningham, Dr. Newmann, and Dr. Kramer.
-
Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation
7/28/2021
Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, announced the initiation of the first-in-human, Phase 1 study in healthy subjects of DISC-0974, a first-in-class inhibitor of hemojuvelin, a novel, genetically validated target for modulating iron metabolism and red blood cell formation.
-
Study: Common Drugs Associated with Increased Risk for Cardiac Arrhythmia and Sudden Death in Elderly Patients
7/28/2021
Certain types of common antibiotic, antidepressant, anti-nausea and anti-platelet drugs are associated with an increased risk of cardiac arrhythmia and sudden death in older patients, according to a study of Medicare claims data authored by researchers from the National Library of Medicine (NLM) and FDB (First Databank, Inc.), the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions.
-
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats
7/28/2021
Touchlight, the leading synthetic DNA manufacturer, is collaborating with the Vanderbilt Vaccine Center at Vanderbilt University Medical Center as part of the DARPA P3 programme.
-
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
7/28/2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.
-
Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
7/28/2021
The ASC22 Phase IIb study is a randomized, single-blind, placebo-controlled, multi-center clinical trial in China which evaluates the safety and efficacy of treating patients with CHB for 24-week treatment of 1 mg/kg or 2.5 mg/kg ASC22 or matching placebo given once every two weeks in combination with NAs.
-
BostonGene Announces Publication in Clinical Cancer Research Identifying the Cellular Features and Gene Expression Characteristics Underlying MRI Visibility in Prostate Cancer
7/28/2021
BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced the online publication of the manuscript, “Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer” in Clinical Cancer Research,
-
The company announced its Malaria project, part of the “eradicateMalaria” initiative led by the kENUP Foundation.
-
One of the eagerly anticipated presentations at the AAIC being held this week is Biogen and its partner Eisai on their controversial drug ADUHELM™ (aducanumab). Biogen is also presenting new data on a different Alzheimer’s drug with another partner, Ionis Pharmaceuticals.